These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 30050387)

  • 1. Cladribine tablets' potential role as a key example of selective immune reconstitution therapy in multiple sclerosis.
    Boyko AN; Boyko OV
    Degener Neurol Neuromuscul Dis; 2018; 8():35-44. PubMed ID: 30050387
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cladribine Tablets for Relapsing-Remitting Multiple Sclerosis: A Clinician's Review.
    Giovannoni G; Mathews J
    Neurol Ther; 2022 Jun; 11(2):571-595. PubMed ID: 35318617
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunological consequences of "immune reconstitution therapy" in multiple sclerosis: A systematic review.
    Sellner J; Rommer PS
    Autoimmun Rev; 2020 Apr; 19(4):102492. PubMed ID: 32062028
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cladribine tablets' potential in multiple: sclerosis treatment.
    Costello K; Sipe JC
    J Neurosci Nurs; 2008 Oct; 40(5):275-80. PubMed ID: 18856248
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The potential role for cladribine in the treatment of multiple sclerosis: clinical experience and development of an oral tablet formulation.
    Leist TP; Vermersch P
    Curr Med Res Opin; 2007 Nov; 23(11):2667-76. PubMed ID: 17880754
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of cladribine tablets on lymphocyte reduction and repopulation dynamics in patients with relapsing multiple sclerosis.
    Comi G; Cook S; Giovannoni G; Rieckmann P; Sørensen PS; Vermersch P; Galazka A; Nolting A; Hicking C; Dangond F
    Mult Scler Relat Disord; 2019 Apr; 29():168-174. PubMed ID: 30885375
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cladribine tablets for the treatment of relapsing-remitting multiple sclerosis.
    Comi G; Hartung HP; Kurukulasuriya NC; Greenberg SJ; Scaramozza M
    Expert Opin Pharmacother; 2013 Jan; 14(1):123-36. PubMed ID: 23256518
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emerging oral treatments in multiple sclerosis - clinical utility of cladribine tablets.
    Gasperini C; Ruggieri S; Pozzilli C
    Ther Clin Risk Manag; 2010 Sep; 6():391-9. PubMed ID: 20856685
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potential mechanisms of action related to the efficacy and safety of cladribine.
    Baker D; Pryce G; Herrod SS; Schmierer K
    Mult Scler Relat Disord; 2019 May; 30():176-186. PubMed ID: 30785074
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cladribine tablets: a potential new short-course annual treatment for relapsing multiple sclerosis.
    Sipe JC
    Expert Rev Neurother; 2010 Mar; 10(3):365-75. PubMed ID: 20187859
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [New directions of immunocorrection in multiple sclerosis].
    Boyko AN; Khachanova NV; Melnikov MV; Sivertseva SA; Evdoshenko EP; Spirin NN; Vasilyev AV; Rozenson OL
    Zh Nevrol Psikhiatr Im S S Korsakova; 2020; 120(2):103-109. PubMed ID: 32307419
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis.
    Giovannoni G; Comi G; Cook S; Rammohan K; Rieckmann P; Soelberg Sørensen P; Vermersch P; Chang P; Hamlett A; Musch B; Greenberg SJ;
    N Engl J Med; 2010 Feb; 362(5):416-26. PubMed ID: 20089960
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neuronal injury in chronic CNS inflammation.
    Zindler E; Zipp F
    Best Pract Res Clin Anaesthesiol; 2010 Dec; 24(4):551-62. PubMed ID: 21619866
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Cladribine tablets : Oral immunotherapy of relapsing-remitting multiple sclerosis with short yearly treatment periods].
    Meuth SG; Ruck T; Aktas O; Hartung HP
    Nervenarzt; 2018 Aug; 89(8):895-907. PubMed ID: 29523912
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of Cladribine Tablets as a Treatment for People With Multiple Sclerosis: Protocol for the CLOBAS Study (Cladribine, a Multicenter, Long-term Efficacy and Biomarker Australian Study).
    Maltby VE; Lea RA; Monif M; Fabis-Pedrini MJ; Buzzard K; Kalincik T; Kermode AG; Taylor B; Hodgkinson S; McCombe P; Butzkueven H; Barnett M; Lechner-Scott J
    JMIR Res Protoc; 2021 Oct; 10(10):e24969. PubMed ID: 34665152
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pulsed immune reconstitution therapy in multiple sclerosis.
    Sorensen PS; Sellebjerg F
    Ther Adv Neurol Disord; 2019; 12():1756286419836913. PubMed ID: 30944586
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and Safety of Intravenous Cladribine in Patients with Rapidly Evolving or Early Secondary Progressive Multiple Sclerosis.
    Alshamrani F; Alnajashi H; Almuaigel MF
    Cureus; 2020 Feb; 12(2):e6995. PubMed ID: 32206459
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Estimating the comparative efficacy of cladribine tablets versus alternative disease modifying treatments in active relapsing-remitting multiple sclerosis: adjusting for patient characteristics using meta-regression and matching-adjusted indirect treatment comparison approaches.
    Berardi A; Siddiqui MK; Treharne C; Harty G; Wong SL
    Curr Med Res Opin; 2019 Aug; 35(8):1371-1378. PubMed ID: 30786783
    [No Abstract]   [Full Text] [Related]  

  • 19. Reduced brain atrophy rates are associated with lower risk of disability progression in patients with relapsing multiple sclerosis treated with cladribine tablets.
    De Stefano N; Giorgio A; Battaglini M; De Leucio A; Hicking C; Dangond F; Giovannoni G; Sormani MP
    Mult Scler; 2018 Feb; 24(2):222-226. PubMed ID: 28140753
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cladribine: mode of action and implications for treatment of multiple sclerosis.
    Leist TP; Weissert R
    Clin Neuropharmacol; 2011; 34(1):28-35. PubMed ID: 21242742
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.